MedTrace Logo

Characterisation of Nasal Polyps in Patients With and Without Aspirin-exacerbated Respiratory Disease

NCT03848156 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 23

Last updated 2020-01-27

No results posted yet for this study

Summary

Prevalence of aspirin-exacerbated respiratory disease (AERD) is 16% amongst patients suffering from chronic rhinosinusitis with nasal polyps (CRSwNP). The mechanisms underlying the observed dysregulation of pro and anti-inflammatory pathways in AERD are still not fully understood. To address this and also to identify potential factors characterizing the disease the investigators plan to prospectively collect blood samples, nasal secretions as well as nasal biopsies from allergic, non-allergic and AERD patients suffering from CRSwNP. Initially, polyps of aforementioned patients will be subjected to RNA sequencing analysis using microarray technology. Once distinct factors are identified in nasal polyp tissue, their presence will be assessed in nasal secretions and serum of the respective patients to investigate their potential role as biomarkers. Furthermore presence of these parameters will be confirmed in situ in biopsies by confocal microscopy. Knowledge about factors differently upregulated in polyp tissue from AERD may contribute to a better understanding of the underlying mechanism of the disease.

Conditions

  • Polyp Sinus

Interventions

OTHER

biopsy

Biopsy of nasal polyp for RNA sequencing

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Medical University of Vienna

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-02-12
Primary Completion
2019-11-30
Completion
2019-11-30

Countries

  • Austria

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03848156 on ClinicalTrials.gov